Photo: Scandistock/Getty Images
Cala Health, maker of wearable neuromodulation therapy for tremors, has received $50 million in growth capital from international alternative asset manager Trinity Capital.
WHAT IT DOES
The California-based bioelectronic medicine company focuses on treating chronic diseases.
Cala Health offers a wearable device designed for individuals with Parkinson's disease and essential tremor, a neurological disorder that causes involuntary shaking in the hands, head, legs or voice.
The company's wearables use transcutaneous afferent patterned stimulation (TAPS), a feature designed to reduce hand tremors by measuring a patient's tremor pattern and delivering individualized nerve stimulation. The therapy is prescribed by a physician and is used at home.
"We are pleased to partner with the Trinity team to optimize our capital structure," Cala CEO Deanna Harshbarger said in a statement. "This collaboration enhances our ability to accelerate commercial expansion and product innovation, advancing Cala TAPS therapy to impact the lives of essential tremor and Parkinson's disease patients."
MARKET SNAPSHOT
The company has received numerous FDA 510(k) clearances, most recently for its Cala kIQ Plus device in March.
The FDA-cleared Cala kIQ Plus device aims to provide temporary relief of hand tremors in adults with essential tremor and provide relief from postural and kinetic hand tremor symptoms in adults with Parkinson's disease.
In 2024, Cala completed the initial closing of an oversubscribed $50 million growth round.
The company secured $77 million in funding in 2021, led by Ascension Ventures. Dolby Family Ventures, PEAK6 Strategic Capital and Innovatus Capital Partners also participated in the round.
Cala Health closed a $55 million Series B round in 2019.
